Postgraduate Medical School, University of Palermo, Palermo, Italy.
University College of Dublin, School of Medicine, Mater Misericordiae University Hospital, Dublin, Republic of Ireland.
Curr Cardiol Rev. 2022;18(5):11-17. doi: 10.2174/1573403X18666220321105909.
In 2020, as the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic spread rapidly throughout the world, scientists worked relentlessly to develop and test the safety and effectiveness of potential vaccines. Usually, the vaccine development process involves years of investigation and testing prior to gaining approval for use in practice. A pathogenic PF4-dependent syndrome, unrelated to the use of heparin therapy, may be manifested following the administration of viral vector vaccines. It leads to severe clot formation at unusual sites approximately in 1 out of 110.000 vaccinated persons. This side effect, although rare, represents a newly devastating clotting phenomenon manifested in otherwise healthy young adults, who are often female. An in-depth description of the specific biological mechanisms implicated in the syndrome is here summarized.
2020 年，随着 2 型严重急性呼吸综合征冠状病毒（SARS-CoV-2）在全球迅速传播，科学家们不懈努力开发和测试潜在疫苗的安全性和有效性。通常，疫苗开发过程需要经过多年的研究和测试，然后才能获得批准用于实际应用。在接种病毒载体疫苗后，可能会出现与肝素治疗无关的、由 PF4 依赖性引起的综合征。它会导致大约每 110000 名接种者中就有 1 人在异常部位出现严重的血栓形成。这种副作用虽然罕见，但代表了一种新的破坏性血栓形成现象，在健康的年轻成年人中表现出来，这些人通常是女性。本文对该综合征所涉及的特定生物学机制进行了深入描述。
